PSNL Personalis, Inc.
Services-Medical Laboratories · Nasdaq · SEC CIK 1527753 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY16.9%
TTM net income YoY-61.5%
TTM EPS YoY-39.8%
Revenue 3-yr CAGR4.6%
Net income 3-yr CAGR—
Margins
Gross margin16.7%
Operating margin-156.7%
Net margin-147.7%
FCF margin-133.3%
EBITDA margin-144.6%
Returns
ROE-62.1%
ROA-44.7%
ROIC (approx.)-84.8%
Asset turnover0.30x
Leverage & solvency
Liabilities / assets27.1%
Debt / equity0.00x
Current ratio4.53x
Interest coverage-683.98x
Cash quality & payout
Operating cash flow / net income0.82x
Accruals ratio-8.1%
Payout ratio—
Capex / revenue12.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $69.65M | $84.61M | $73.48M | $65.05M | $85.49M |
| Cost of revenue | $53.87M | $57.79M | $55.27M | $51.70M | $53.84M |
| Gross profit | $15.78M | $26.82M | $18.21M | $13.35M | $31.66M |
| R&D expense | $50.26M | $48.91M | $64.78M | $64.91M | $49.31M |
| SG&A expense | $53.57M | $46.19M | $49.73M | $63.97M | $47.70M |
| Operating income | -$88.06M | -$68.27M | -$109.94M | -$115.53M | -$65.35M |
| Interest expense | $205,000 | $24,000 | $110,000 | $201,000 | $184,000 |
| Pretax income | -$81.25M | -$81.27M | -$108.21M | -$113.28M | -$65.21M |
| Income tax | $21,000 | $18,000 | $83,000 | $40,000 | $14,000 |
| Net income | -$81.27M | -$81.28M | -$108.30M | -$113.31M | -$65.23M |
| EBITDA | -$78.01M | -$57.33M | -$98.64M | -$107.10M | -$59.34M |
| EPS (basic) | -0.91 | -1.37 | -2.25 | -2.48 | -1.49 |
| EPS (diluted) | -0.91 | -1.37 | -2.25 | -2.48 | -1.49 |
| Weighted avg. shares (diluted) | 89.24M | 59.25M | 48.18M | 45.70M | 43.89M |
| Balance sheet | |||||
| Cash & equivalents | $124.25M | $91.42M | $56.98M | $89.13M | $105.58M |
| Short-term investments | $115.71M | $93.59M | $57.20M | $78.53M | $181.48M |
| Receivables | $16.20M | $8.14M | $17.73M | $16.64M | $18.47M |
| Current assets | $267.95M | $203.01M | $146.74M | $199.70M | $318.23M |
| PP&E, net | $44.81M | $48.27M | $57.37M | $61.94M | $19.65M |
| Total assets | $334.16M | $270.27M | $225.10M | $292.70M | $396.53M |
| Current liabilities | $39.63M | $31.13M | $47.23M | $33.13M | $31.31M |
| Total liabilities | $72.98M | $67.31M | $95.66M | $74.56M | $86.23M |
| Shareholders' equity | $261.19M | $202.96M | $129.44M | $218.14M | $310.30M |
| Shares outstanding | 102.48M | 85.17M | 50.48M | 46.71M | 44.90M |
| Cash flow statement | |||||
| Operating cash flow | -$74.95M | -$45.15M | -$56.26M | -$70.23M | -$70.83M |
| Capital expenditure | $4.50M | $1.60M | $10.91M | $49.90M | $11.08M |
| Free cash flow | -$79.45M | -$46.75M | -$67.17M | -$120.13M | -$81.91M |
| Investing cash flow | -$22.57M | -$35.07M | $13.10M | $52.54M | -$60.07M |
| Financing cash flow | $130.34M | $114.67M | $11.03M | $1.37M | $169.70M |
| Depreciation & amortization | $10.05M | $10.94M | $11.30M | $8.43M | $6.01M |
| Stock-based compensation | $9.43M | $10.69M | $14.05M | $19.43M | $14.38M |
Free plan shows the latest 5 periods; Pro shows all 9 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.